IONSIonis Pharmaceuticals Inc
Slide 1 of 3
Company Overview
Name
Ionis Pharmaceuticals Inc
52W High
$82.95
52W Low
$23.95
Market Cap
Dividend Yield
0%
Price/earnings
-0.8
P/E
-0.8
Dividends
No dividend
Sentiment
Score
Bullish
60
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 2 of 3
Income Statement
Total Revenue
$156.7M
Operating Revenue
$156.7M
Total Gross Profit
$154.4M
Total Operating Income
$-160.2M
Net Income
$-128.6M
EV to EBITDA
$0.00
EV to Revenue
$0.00
Price to Book value
$0.00
Price to Earnings
$0.00
Additional Data
Selling, General & Admin Expense
$96.8M
Research & Development Expense
$217.8M
Total Operating Expenses
$-314.6M
Interest Expense
$-22.2M
Interest & Investment Income
$53.6M
Other Income / (Expense), net
$363K
Slide 3 of 3
Earnings History
Estimated EPS
Reported EPS
N/A Slide 1 of 5
Company Overview
Name
Ionis Pharmaceuticals Inc
52W High
$82.95
52W Low
$23.95
Market Cap
Dividend Yield
0%
Price/earnings
-0.8
P/E
-0.8
Dividends
No dividend
Slide 2 of 5
Sentiment
Score
Bullish
60
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 3 of 5
Income Statement
Total Revenue
$156.7M
Operating Revenue
$156.7M
Total Gross Profit
$154.4M
Total Operating Income
$-160.2M
Net Income
$-128.6M
EV to EBITDA
$0.00
EV to Revenue
$0.00
Price to Book value
$0.00
Price to Earnings
$0.00
Slide 4 of 5
Additional Data
Selling, General & Admin Expense
$96.8M
Research & Development Expense
$217.8M
Total Operating Expenses
$-314.6M
Interest Expense
$-22.2M
Interest & Investment Income
$53.6M
Other Income / (Expense), net
$363K
Slide 5 of 5
Earnings History
Estimated EPS
Reported EPS
N/AUpcoming Earnings
We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
Brett P. Monia
Location
California, USA
Exchange
Nasdaq
Website
https://ionispharma.com
Summary
Ionis Pharmaceuticals, Inc.
Company Info
CEO
Brett P. Monia
Location
California, USA
Exchange
Nasdaq
Website
https://ionispharma.com
Summary
Ionis Pharmaceuticals, Inc.
